Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase II study of this combination in patients with inoperable or with postoperative gastric cancer
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0303|
- objective tumor response
- Response duration, time to progression, median survival time, and safety will also be assessed.
|Study Start Date:||January 2004|
|Estimated Study Completion Date:||December 2008|
A multicenter Open-label, single-arm, phase II clinical trial is conducted on patients with histological stage IV gastric cancer given irinotecan plus S-1. The usefulness of this regimens as 1st line therapy for gastric cancer was evaluated by the disease-free survival rate (DFR), overall survival rate (OS), incidence and severity of adverse event.
|Hokkaido University Hospital|
|Sapporo, Hokkaido, Japan, 060-8638|
|Study Chair:||Yoshito Komatsu, MD, PhD||Hokkaido Gastrointestinal Cancer Study Group|